Prognostic impact of tumor size eliminating the ground glass opacity component modified clinical t descriptors of the tumor, node, metastasis classification of lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 12, 2013, Pages 1551-1557

  Nakamura, Shota ^a   Fukui, Takayuki ^a   Taniguchi, Tetsuo ^a   Usami, Noriyasu ^a   Kawaguchi, Koji ^a   Ishiguro, Futoshi ^a   Hirakawa, Akihiro ^a   Yokoi, Kohei ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Ground glass opacity; Lung cancer; Metastasis classification; Node; Staging; Tumor; Tumor size

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GROUND GLASS OPACITY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; SURVIVAL RATE; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT; ADENOCARCINOMA; CLASSIFICATION; FOLLOW UP; LUNG ALVEOLUS CELL CARCINOMA; LUNG TUMOR; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; SECONDARY; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84892158109     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000020     Document Type: Article

References (31)

1. Sone S, Takashima S, Li F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998;351:1242-1245.
2. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99-105.
3. Kaneko M, Eguchi K, Ohmatsu H, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996;201:798-802.
4. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75(1 Suppl):191-202.
5. Hung JJ, Jeng WJ, Chou T Y, et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg 2013 In press.
6. Park MC, G MJ, Lee HC, et al. Nodular ground-glass opacity at thin-section CT: histologic correlation and evaluation of change at follow-up. RadioGraphics 2007;27:391-408.
7. Kuriyama K, Seto M, Kasugai T, et al. Ground-glass opacity on thin-section CT: value in differentiating subtypes of adenocarcinoma of the lung. AJR Am J Roentgenol 1999;173:465-469.
8. Suzuki K, Yokose T, Yoshida J, et al. Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. Ann Thorac Surg 2000;69:893-897.
9. Matsuguma H, Nakahara R, Anraku M, et al. Objective definition and measurement method of ground-glass opacity for planning limited resection in patients with clinical stage IA adenocarcinoma of the lung. Eur J Cardiothorac Surg 2004;25:1102-1106.
10. Lee MS, Park MC, Lee H-J, et al. Invasive pulmonary adenocarcinomas versus preinvasive lesions appearing as ground-glass nodules: differentiation by using CT features. Radiology 2013;268:265-273.
11. Higashiyama M, Kodama K, Yokouchi H, et al. Prognostic value of bron-chiolo-alveolar carcinoma component of small lung adenocarcinoma. Ann Thorac Surg 1999;68:2069-2073.
12. Macchiarini P, Fontanini G, Hardin JM, et al. Most peripheral, node-negative, non-small-cell lung cancers have low proliferative rates and no intratumoral and peritumoral blood and lymphatic vessel invasion. Rationale for treatment with wedge resection alone. J Thorac Cardiovasc Surg 1992;104:892-899.
13. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.
14. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.
15. Goldstraw P, Crowley J, Chansky K, et al. International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714.
16. Tsutani Y, Miyata Y, Nakayama H, et al. Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: a multicenter study. J Thorac Cardiovasc Surg 2012;143:607-612.
17. Matsuguma H, Oki I, Nakahara R, et al. Comparison of three measurements on computed tomography for the prediction of less invasiveness in patients with clinical stage I non-small cell lung cancer. Ann Thorac Surg 2013;95:1878-1884.
18. Maeyashiki T, Suzuki K, Hattori A, et al. The size of consolidation on thin-section computed tomography is a better predictor of survival than the maximum tumour dimension in resectable lung cancer. Eur J Cardiothorac Surg 2013;43:915-918.
19. Sauerbrei W, Hübner K, Schmoor C, Schumacher M. Validation of existing and development of new prognostic classification schemes in node negative breast cancer. German Breast Cancer Study Group. Breast Cancer Res Treat 1997;42:149-163.
20. Mountain C F, Carr DT, Anderson WA. A system for the clinical staging of lung cancer. Am J Roentgenol Radium Ther Nucl Med 1974;120:130-138.
21. Nakata M, Saeki H, Takata I, et al. Focal ground-glass opacity detected by low-dose helical CT. Chest 2002;121:1464-1467.
22. Jang HJ, Lee KS, Kwon OJ, Rhee CH, Shim YM, Han J. Bronchioloalveolar carcinoma: focal area of ground-glass attenuation at thin-section CT as an early sign. Radiology 1996;199:485-488.
23. Matsuguma H, Yokoi K, Anraku M, et al. Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1 N0 M0 adenocarcinoma of the lung: a predictor of lymph node metastasis. J Thorac Cardiovasc Surg 2002;124:278-284.
24. Suzuki K, Koike T, Asakawa T, et al. A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol 2012;143:607-612.
25. Asamura H, Hishida T, Suzuki K, et al; Japan Clinical Oncology Group Lung Cancer Surgical Study Group. Radiographically determined noninvasive adenocarcinoma of the lung: survival outcomes of Japan Clinical Oncology Group 0201. J Thorac Cardiovasc Surg 2013;146:24-30.
26. Okada M, Tauchi S, Iwanaga K, et al. Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas. J Thorac Cardiovasc Surg 2007;133:1448-1454.
27. Kodama K, Higashiyama M, Yokouchi H, et al. Prognostic value of ground-glass opacity found in small lung adenocarcinoma on high-resolution CT scanning. Lung Cancer 2001;33:17-25.
28. Ohde Y, Nagai K, Yoshida J, et al. The proportion of consolidation to ground-glass opacity on high resolution CT is a good predictor for distinguishing the population of non-invasive peripheral adenocarcinoma. Lung Cancer 2003;42:303-310.
29. Okada T, Iwano S, Ishigaki T, et al. Computer-aided diagnosis of lung cancer: definition and detection of ground-glass opacity type of nodules by high-resolution computed tomography. Jpn J Radiol 2009;27:91-99.
30. Christian W. TNM Supplement: A Commentary on Uniform Use, 4th Ed. UICC. Wiley, 2012.
31. Okada M, Nakayama H, Okumura S, et al. Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma. J Thorac Cardiovasc Surg 2011;141:1384-1391.